61 completed, 9 recruiting, 7 terminated, 4 unknown. 49 Phase 3, 29 Phase 2, 8 Phase 1, 8 Phase 4, 3 Not applicable.
Follow gamma-Globulins: new trials by email Literature Review of gamma-Globulins trials Research Report on gamma-Globulins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With Immunoglobulins TAK-664 - Primary Immunodeficiency Diseases (PID) | Phase 4 | Not yet recruiting | Takeda | 9 | 2026-11-01 | 2026-09-08 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) IgPro - Primary Immunodeficiency | Phase 4 | Completed | CSL Behring | 8 | 2025-07-15 | 2026-07-16 |
| Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy Immune Globulin Intravenous (Human), 10%, Immune Globulin Subcutaneous (Human), 20% Solution - Hypogammaglobulinemia, Acquired | Recruiting | University of Alberta | 30 | 2025-06-01 | 2026-09-24 | |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-07 | 2025-10-07 |
| A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) TAK-881, HYQVIA, SC Investigational Needle Sets - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 3 | Recruiting | Takeda | 59 | 2025-05-06 | 2026-01-20 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) Trimethoprim Sulfamethoxazole, Amoxycillin/clavulanic acid, Immune Globulin Intravenous - Myeloma, Leukemia | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults TAK-881, SC Investigational Needle Sets - Healthy Volunteers | Phase 1 | Completed | Takeda | 64 | 2025-04-22 | 2026-08-17 |
| A Study of TAK-881 and HyQvia in Healthy Adults TAK-881, HyQvia, SC Investigational Needle Sets - Healthy Volunteers | Phase 1 | Completed | Takeda | 30 | 2025-03-24 | 2026-06-11 |
| A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency Immune Globulin Subcutaneous (Human), 20% Solution - Primary Immunodeficiency Diseases (PID) | Recruiting | Takeda | 100 | 2025-02-17 | 2026-08-07 | |
| Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy Immunoglobulins IV (CLAYRIG), Cyclophosphamide IV, Methylprednisolone IV - Paraneoplastic Sensory Neuronopathy | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 21 | 2025-01-10 | 2025-02-17 |
| A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US) - Primary Immunodeficiency Diseases (PID) | Phase 3 | Active not recruiting | Takeda | 53 | 2024-11-04 | 2026-04-08 |
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases TAK-881, HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Takeda | 65 | 2023-10-24 | 2026-09-30 |
| Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy - COPD Exacerbation Acute | Phase 2 | Unknown | Rochester General Hospital | 40 | 2023-06-01 | 2023-06-15 |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | Grifols Therapeutics LLC | 386 | 2022-12-26 | 2026-09-30 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Crovalimab, Placebo, Intravenous immunoglobulin therapy - Guillain-Barré Syndrome | Phase 3 | Withdrawn | Hoffmann-La Roche | 2022-11-30 | 2022-12-15 | |
| A Study of TAK-881 in Healthy Adults TAK-881 - Healthy Volunteers | Phase 1 | Completed | Takeda | 24 | 2021-10-12 | 2024-01-12 |
| Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY) Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg) - Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS) | Phase 3 | Completed | University Children's Hospital Basel | 76 | 2021-05-23 | 2025-02-13 |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 1 | 2021-01-07 | 2026-09-29 |
Showing 20 of 89. Sign in to see all of them.
Primary Immunodeficiency Diseases (33) · Common Variable Immunodeficiency (7) · Immunologic Deficiency Syndromes (7) · Agammaglobulinemia (6) · Bruton type agammaglobulinemia (5) · Hyper-IgM Immunodeficiency Syndrome (5) · Leukemia (5) · Purpura, Thrombocytopenic, Idiopathic (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (4) · Neoplasms, Plasma Cell (4) · Wiskott-Aldrich Syndrome (4) · COVID-19 (3) · Infections (3) · Neoplasms (3)
Baxalta now part of Shire (13) · CSL Behring (10) · Grifols Therapeutics LLC (10) · Takeda (9) · Bio Products Laboratory (6) · Instituto Grifols, S.A. (3) · Monash University (3) · ADMA Biologics, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · Green Cross Corporation (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Octapharma (2) · Albert Einstein College of Medicine (1) · Biopharma Plasma LLC (1) · Biotest (1)
United States (56) · Canada (18) · Germany (14) · Poland (14) · Spain (13) · United Kingdom (12) · Czechia (9) · France (9) · Italy (9) · Hungary (8) · Japan (8) · Australia (7) · Denmark (6) · Sweden (6) · Argentina (5)
Zoe McQuilten, Professor (3) · Chaim Roifman, MD (2) · James Moy, MD (2) · Aihua Zhang, M.D. (1) · Akhilesh Chouksey, MD (1) · Bernd Kieseier, MD (1) · Beverly C Walters, MD (1) · Cliff Librach, MD (1) · Daniel Suez, MD (1) · David Wessels, MBChB MBA (1) · Didier Blaise, MD (1) · Dimitri Psimaras, MD (1)
PMID 36818468, PMID 30626238, PMID 31268374, PMID 34036490, PMID 18178525, PMID 18645164, PMID 19260050, PMID 19365055, PMID 19496683, PMID 20386074, PMID 20454851, PMID 20457948, PMID 20634190, PMID 20647554, PMID 20837852, PMID 20863431, PMID 21424824, PMID 21553933, PMID 21674136, PMID 21692906, PMID 21705277, PMID 24504846, PMID 24892422, PMID 25090414, PMID 27582171, PMID 27613250, PMID 28381506, PMID 29376112, PMID 31228628, PMID 31621458, PMID 32301062, PMID 32967877, PMID 33568350, PMID 34305948, PMID 34473343, PMID 34931880, PMID 35669398, PMID 35867135, PMID 35934726, PMID 35944615, PMID 36383294, PMID 36456193, PMID 36746174, PMID 36853224, PMID 38107550, PMID 38129731, PMID 38489186, PMID 38670610, PMID 38978354, PMID 39271296
2023 (3), 2009 (2), 2015 (2), 2017 (1), 2018 (1), 2019 (1), U10CA013539 (1), U10CA098543 (1), U10CA180886 (1), UG1CA189828 (1)